Enanta Pharmaceuticals, Inc. (ENTA)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
13.64 USD
-0.06
(-0.438%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:16 a.m. EDT
The investment case here is fundamentally broken despite the recent price bounce. The company is in a severe multi-year structural decline, having lost over 70% of its value over the last nine years with three consecutive years of negative returns ending recently. While the stock has rallied recently—likely driven by clinical trial updates on its RSV drug—the underlying business metrics remain dire: negative earnings, negative operating cash flow, and a return on equity of nearly -59%. The market is pricing in significant distress, which is reflected in the overwhelming options activity where traders are buying deep puts rather than betting on rallies. The recent price strength appears to be a temporary relief rally against a backdrop of deteriorating fundamentals and a fortress-like balance sheet that is actually eroding due to debt obligations. Until there is clear, sustained evidence of profitability or a definitive path to cash-flow positivity, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.074337 |
| AutoETS | 0.089391 |
| AutoARIMA | 0.090037 |
| MSTL | 0.096039 |
| MSTL_79 | 0.129331 |
| MSTL_115 | 0.133132 |
| MSTL_79_115 | 0.165212 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 2.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.180 |
| Excess Kurtosis | -0.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 160.067 |
| Revenue per Share | 2.754 |
| Market Cap | 396,629,120 |
| Forward P/E | -6.66 |
| Beta | 0.97 |
| Profit Margins | -89.55% |
| Website | https://www.enanta.com |
As of July 11, 2026, 3:16 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $7.50, $10.00, $12.50) compared to negligible call volume. The put/call ratio is skewed significantly toward hedging or bearish bets, while call activity remains thin and concentrated at strikes far above the current price, indicating a lack of immediate bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9683908 |
| Address1 | 4 Kingsbury Avenue |
| All Time High | 127.77 |
| All Time Low | 4.09 |
| Ask | 17.25 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 312,690 |
| Average Daily Volume3 Month | 211,665 |
| Average Volume | 211,665 |
| Average Volume10Days | 312,690 |
| Beta | 0.967 |
| Bid | 9.88 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 4.012 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.64 |
| Current Ratio | 3.842 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 13.97 |
| Day Low | 13.43 |
| Debt To Equity | 160.067 |
| Display Name | Enanta Pharmaceuticals |
| Earnings Call Timestamp End | 1,715,027,400 |
| Earnings Call Timestamp Start | 1,715,027,400 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,392,000 |
| Earnings Timestamp Start | 1,786,392,000 |
| Ebitda | -55,451,000 |
| Ebitda Margins | -0.80116 |
| Enterprise To Ebitda | -7.565 |
| Enterprise To Revenue | 6.061 |
| Enterprise Value | 419,472,096 |
| Eps Current Year | -1.88 |
| Eps Forward | -2.048 |
| Eps Trailing Twelve Months | -2.6 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 607 0530 |
| Fifty Day Average | 13.4764 |
| Fifty Day Average Change | 0.16359997 |
| Fifty Day Average Change Percent | 0.012139738 |
| Fifty Two Week Change Percent | 96.83908 |
| Fifty Two Week High | 17.15 |
| Fifty Two Week High Change | -3.5099993 |
| Fifty Two Week High Change Percent | -0.20466469 |
| Fifty Two Week Low | 6.435 |
| Fifty Two Week Low Change | 7.2050004 |
| Fifty Two Week Low Change Percent | 1.1196582 |
| Fifty Two Week Range | 6.435 - 17.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,363,872,600,000 |
| Float Shares | 20,059,139 |
| Forward Eps | -2.048 |
| Forward P E | -6.6601562 |
| Free Cashflow | 7,687,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 120 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 69,213,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04684 |
| Held Percent Institutions | 0.92736 |
| Implied Shares Outstanding | 29,078,380 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Long Business Summary | Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. |
| Long Name | Enanta Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 396,629,120 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_345286 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -61,984,000 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 396,629,103 |
| Number Of Analyst Opinions | 6 |
| Open | 13.43 |
| Operating Cashflow | -7,838,000 |
| Operating Margins | -0.69071996 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 617 607 0800 |
| Previous Close | 13.7 |
| Price Eps Current Year | -7.255319 |
| Price Hint | 2 |
| Price To Book | 3.3998005 |
| Price To Sales Trailing12 Months | 5.730558 |
| Profit Margins | -0.89555 |
| Quick Ratio | 3.695 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.0599995 |
| Regular Market Change Percent | -0.437952 |
| Regular Market Day High | 13.97 |
| Regular Market Day Low | 13.43 |
| Regular Market Day Range | 13.43 - 13.97 |
| Regular Market Open | 13.43 |
| Regular Market Previous Close | 13.7 |
| Regular Market Price | 13.64 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 136,137 |
| Return On Assets | -0.118360005 |
| Return On Equity | -0.58997 |
| Revenue Growth | 0.15 |
| Revenue Per Share | 2.754 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,078,380 |
| Shares Percent Shares Out | 0.0888 |
| Shares Short | 2,583,579 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,274,248 |
| Short Name | Enanta Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.106400006 |
| Short Ratio | 10.17 |
| Source Interval | 15 |
| State | MA |
| Symbol | ENTA |
| Target High Price | 28.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 21.16667 |
| Target Median Price | 20.0 |
| Total Cash | 163,774,000 |
| Total Cash Per Share | 5.632 |
| Total Debt | 186,616,992 |
| Total Revenue | 69,213,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.113525 |
| Two Hundred Day Average Change | 0.52647495 |
| Two Hundred Day Average Change Percent | 0.040147476 |
| Type Disp | Equity |
| Volume | 136,137 |
| Website | https://www.enanta.com |
| Zip | 2,472 |